GINA HEBERLIE: Open Payments
NPI 1316053028 · FARMINGTON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,906 in 85 payments from 28 companies in 2025. Trend: 2023 $3,495 · 2024 $3,580 · 2025 $1,906
Food & beverage: $1,906
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $324 |
| Lilly USA, LLC | 6 | $191 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $146 |
| Axsome Therapeutics, Inc. | 5 | $134 |
| Aimmune Therapeutics, Inc. | 4 | $128 |
| Novo Nordisk Inc | 4 | $111 |
| PFIZER INC. | 5 | $109 |
| Teva Pharmaceuticals USA, Inc. | 2 | $92 |
| Alexion Pharmaceuticals, Inc. | 1 | $79 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $71 |
Products named: MOUNJARO, VRAYLAR, CAPLYTA, Auvelity, ZENPEP, ELIQUIS, Ozempic, AUSTEDO XR.
Industry payments across MO — which companies pay providers there.
